Skip to content
Research Article Open access CC BY 4.0

Proposal and Point of View on Targeting α-synuclein for the Treatment of Parkinson's Disease

Yong-Peng Yu

Advances in Research · pp. 1–5 · Published 2 Dec 2015

10.9734/AIR/2016/22584

Abstract

Many scientific studies in the biochemical, genetic fields suggest that there were common mechanisms, such as genes, α-synuclein protein, tau protein, oxidative stress, mitochondrial dysfunction, and iron might be shared in Alzheimer disease (AD) and Parkinson disease (PD). α-synuclein is suggested to have a vital role in the pathogenesis of PD and is a promising therapeutic target. However, gap might always exist between clinical and basic researches. The failure of recent phase III trials of the anti-Amyloid-β (Aβ) monoclonal for AD prompts us to rethink PD therapy strategies. As multiple mechanisms are involved in PD pathogenesis and their relative roles might vary at different stages of this disease. Use of comprehensive prevention strategies and targets at different stages of PD might be a promising way to cure or prevent PD in the future.

Alzheimer disease Parkinson disease α-synuclein neurodegeneration amyloid-β

References (15)

  1. 1 α-Synuclein Locus Triplication Causes Parkinson's Disease [DOI]
  2. 2 α-synuclein locus duplication as a cause of familial Parkinson's disease [DOI]
  3. 3 Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease [DOI]
  4. 4 Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease [DOI]
  5. 5 Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease [DOI]
  6. 6 Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? [DOI]
  7. 7 Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization [DOI]
  8. 8 Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission [DOI]
  9. 9 Anti-inflammatory drugs and risk of Parkinson disease [DOI]
  10. 10 Use of ibuprofen and risk of Parkinson disease [DOI]
  11. 11 The role of α-synuclein in neurodegenerative diseases [DOI]
  12. 12 The role of inflammation in sporadic and familial Parkinson’s disease [DOI]
  13. 13 Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease [DOI]
  14. 14 Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View [DOI]
  15. 15 PARKINSON’S DISEASE, AUTOIMMUNITY, AND OLFACTION [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

66

Page views

0

PDF downloads

11

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.